Moreover, some patients with MPD have clinico-hematologic features resembling MDS at the first manifestation: some of them progress into MPD several years later. The WHO criteria may not cover all of these heterogeneous entities, therefore, we should probably diagnose such patients tentatively at the present juncture. For example, late appearing myelofibrosis in MDS patients should not be categorized as MDS/MPD at the first manifestation.
In our current study published in Leukemia, 6 we did not have the chance to identify the JAK2 V617F mutation during the MDS phase lacking myelofibrosis. We detected the mutation in the myelofibrosis phase; therefore, we considered that the difference of the JAK2 V617F mutation, 6 unlike the contention of Kremer et al., 3 might mainly be owing to different diagnostic categorization. Owing to the lack of a concrete diagnostic definition of MDS with myelofibrosis, we cannot completely eliminate the possibility of overestimating 'true' MDS with myelofibrosis, but we do not know the biological or definite clinical significance of the disease, and such an overestimation may cause some confusion concerning the data on the JAK2 V617F mutation.
Eventually, as Kremer et al. 3 also suggested, MDS/MPD might be one domain of MDS, but probably only a part of even those may show the JAK2 V617F mutation, as about 90% of polycythemia vera and 50% of essential thrombocythemia or primary myelofibrosis carry this mutation. Therefore, we can only say that the JAK2 V617F mutation might be one diagnostic tool for the identification of MPD. An accumulation of conditions overlapping MDS to ascertain degree, including a compilation of the MPD-like clinico-hematologic features, in combination with the detection of the JAK2 V617F mutation, might be required to resolve the problematic topology of MDS with myelofibrosis. A novel approach to eliminate residual disease after human leucocyte antigen (HLA)-matched stem cell transplantation (SCT) for leukaemia is tumour-specific adoptive immunotherapy. Excellent immunotherapeutic targets for adoptive immunotherapy are the haematopoietic system-specific minorhistocompatibility antigens (mHags) HA-1 and HA-2, which are expressed on all normal and malignant haematopoietic cells. ).
Here, we describe an isochromosome 7 causing loss of HA-2 CTL recognition of leukaemic cells in a patient with pre-B acute lymphoblastic leukaemia. The patient was typed on PBMCs to be heterozygous for both HA-1 (H/R) and HA-2 (V/M) (Figure 1e and f ). The leukaemia karyotype was 46,XX,i(7)(q10),der(19)t (1;19)(q23;p13). Hereby, the HA-1 encoding region on one chromosome 19 and the HA-2 encoding region on one chromosome 7 were deleted (Figure 1a) . The bone marrow of the patient contained 90% leukaemic blasts. We separated these CD10 positive leukaemia cells from nonleukaemic cells with magnetic beads and used them as targets in a chromium release assay. HA-1 CTLs effectively lysed the isolated leukaemic cells and a leukaemia cell line derived from the same patient (Figure 1b) . In contrast, HA-2 CTLs did not lyse the leukaemia cells. Phytohaemagglutinin blasts of the patient and the CD10 negative bone marrow fraction were, however, well recognised by HA-2 CTLs. Low recognition of unseparated bone marrow cells is explained by the high percentage of HA-2 nonexpressing leukaemia cells (Figure 1c) . We subsequently repeated genomic mHag HA-1 and HA-2 typing on highly purified leukaemia cells (Figure 1d-f) . Both, HA-1R and HA-2V were absent in the leukaemia cells, while present in PBMCs and the nonleukaemic bone marrow fraction. Thus, the chromosomal aberrations had deleted the nonimmunogenic HA-1R allele and the immunogenic HA-2V allele, concordant with the functional results.
Here, we have shown as proof of principle that common karyotypic abnormalities in leukaemia cells can knockout mHag encoding genes and thereby abrogate their recognition by mHag CTLs. This antigen presentation defect is restricted to a very limited number of antigens, namely those affected by the chromosomal aberration. It differs thereby from previously described immune escape mechanisms like loss/downregulation of HLA expression 6 or peptide processing defects, 7 which broadly abolish antigen recognition on malignant cells. Consequently, the observed mechanism of mHag loss requires particular attention when targeting specific mHags with immunotherapy.
Chromosomal aberrations affecting mHag encoding genes are critical for mHag-specific leukaemia recognition mainly in mHag heterozygous patients ('mHag heterozygous' means generally, that these patients have one immunogenic and one nonimmunogenic mHag allele). In these patients, loss of the single immunogenic mHag allele may completely abrogate leukaemia recognition by mHag CTLs. The risk of mHag HA-1 or HA-2 loss in haematological malignancies can be assessed as follows: owing to the restriction of the HA-1 and HA-2 epitopes to HLA-A2, only HLA-A2 positive patients can be affected by a loss of leukaemia recognition by HA-1 or HA-2 CTLs. Aberrations on chromosome 19 (harbouring the HA-1 gene) and 7 (harbouring the HA-2 gene) mainly occur in childhood acute lymphoblastic leukaemia and secondary myeloid leukaemia, respectively. 3 The risk of mHag HA-1 or HA-2 gene loss is thus largely restricted to these haematological malignancies. Approximately 50% of the individuals are HA-1 H/R hetero- Figure 1 Chromosomal, minor-histocompatibility antigen (mHag) allelic and functional characterisation of the studied leukaemia. Letters to the Editor zygous and 35% are HA-2 V/M heterozygous. 8 This means that both HA-1 and HA-2 heterozygosity are frequent in the population. Therefore, HLA-A2 positive leukaemias with HA-1 or HA-2 gene affecting karyotypes might be occasionally unrecognised by HA-1 or HA-2 CTLs.
In conclusion, mHag loss due to chromosomal aberrations has relevant implications for the eligibility of patients for mHagspecific immunotherapy. Confirmation of the mHag genotype on purified leukaemia cells is essential in mHag heterozygous patients with a leukaemia karyotype involving the mHag encoding gene.
